Susan Bobulsky Sells 3,000 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 3,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the sale, the insider directly owned 396,989 shares in the company, valued at $9,924,725. This represents a 0.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.00, for a total transaction of $31,176.00.
• On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $22.00, for a total transaction of $10,714.00.
• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $24.46 on Friday. The company has a fifty day simple moving average of $21.12 and a two-hundred day simple moving average of $17.06. The company has a market cap of $3.90 billion, a price-to-earnings ratio of -59.66 and a beta of 2.08. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a 52 week low of $11.92 and a 52 week high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The firm’s revenue was up 21.5% on a year-over-year basis. As a group, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $324,735,000. Westfield Capital Management Co. LP purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $65,942,000. Price T Rowe Associates Inc. MD grew its position in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after buying an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Adaptive Biotechnologies by 248.8% during the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after acquiring an additional 2,216,595 shares in the last quarter. 99.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen raised their price objective on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.